GlassScriptPhysician profile
Seth D Rosen
NPI 1457389983
$19,941.68
in general payments reported to CMS, 2019-2025
51 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,253 · 2020: $2,232 · 2021: $4,175 · 2022: $2,585 · 2023: $3,197 · 2024: $2,555 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,594 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,593.87 |
| Education | $102.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,577.13 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $2,083.45 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,979.91 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $1,719.22 | 2019-2025 | Sucraid, Sucraid |
| Pharmacosmos Therapeutics INC. | $1,542.46 | 2021-2024 | Monoferric |
| Celgene Corporation | $1,050.73 | 2021-2024 | Zeposia, Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $736.19 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $707.70 | 2022-2025 | |
| Gilead Sciences, INC. | $674.13 | 2019-2025 | |
| Ardelyx, INC. | $522.99 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $515.81 | 2019-2025 | Ocaliva |
| Boston Scientific Corporation | $507.86 | 2019-2023 | Exalt Model D, Spyscope Ds |
| Redhill Biopharma INC. | $504.94 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $503.34 | 2019-2024 | Linzess |
| Celltrion USA INC. | $405.88 | 2024-2025 | Vegzelma |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $354.00 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $307.42 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $296.40 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $252.13 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $234.22 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $209.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $193.31 | 2019-2025 | Rebyota, Clenpiq |
| Pfizer INC. | $190.12 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $167.22 | 2019-2021 | |
| Allergan, INC. | $151.79 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $151.36 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $150.22 | 2023-2024 | Voquezna |
| Medtronic, INC. | $147.92 | 2025 | Pillcam |
| Alfasigma USA, INC. | $103.40 | 2020-2022 | |
| Evoke Pharma, INC. | $97.11 | 2021-2025 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $90.98 | 2019-2023 | Zeposia |
| Genentech USA, INC. | $88.00 | 2025 | Tecentriq, Venclexta |
| Vivus LLC | $86.20 | 2021-2025 | Qsymia, Pancreaze |
| Novo Nordisk INC | $80.62 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $75.80 | 2024-2025 | Iqirvo |
| Exact Sciences Corporation | $70.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Braintree Laboratories, INC. | $59.14 | 2019-2024 | Suflave |
| Alnylam Pharmaceuticals INC. | $48.50 | 2022-2024 | Givlaari |
| Concordia Pharmaceuticals INC. | $42.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.89 | 2019 | |
| Fresenius Kabi USA, LLC | $33.63 | 2023 | |
| Tersera Therapeutics LLC | $31.44 | 2024 | Zoladex |
| Romark Laboratories, Lc | $25.08 | 2020 | |
| Beigene USA, INC. | $24.54 | 2020 | |
| Amgen INC. | $21.46 | 2020 | |
| Blueprint Medicines Corporation | $19.48 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $16.12 | 2021 | |
| Ucb, INC. | $14.97 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.70 | 2023 | Andexxa |
| Pentax of America, INC. | $11.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.